×
About 1,035,930 results

ASL Video Series: V-safe After Vaccination Health Checker
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/426365

The v-safe health checker is a tool that is available to you after you receive a COVID-19 vaccination More COVID-19 information in ASL: https://www.youtube.com/playlist?list=PLvrp9iOILTQatwnqm61jqFrsfUB4RKh6J More COVID-19 information in English text: https://www.cdc.gov/coronavirus/ Development of these materials was supported by a grant from the CDC Foundation, using funding provided...

ASL Video Series: How to Talk About COVID-19 Vaccines with Friends and Family
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/426366

COVID-19 vaccines help prevent COVID-19, especially severe illness and death. Getting vaccinated will help protect you and may also help protect people around you, including people at increased risk for severe illness from COVID-19. COVID-19 vaccination is an important tool to help stop the pandemic. More COVID-19 information in ASL: https://www.youtube.com/playlist?list=PLvrp9iOILTQatwnqm61...

Potandon Produce Voluntarily Recalls Select Red, White, and Yellow Whole Onions Because of Possible Health Risk
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428248

Potandon Produce L.L.C. ofldaho Falls, Idaho is voluntarily recalling Green Giant Fresh whole yellow onions in 2 lb. bags, 3 lb. bags, and 5 lb. bags; whole white onions in 2 lb. bags; and whole red onions in 2 lb. bags delivered directly to three UNFI retail distribution centers (DCs) in Fargo, Nor

Potandon Produce Voluntarily Recalls Select Red, White, and Yellow Whole Onions Because of Possible Health Risk
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428247

Potandon Produce L.L.C. ofldaho Falls, Idaho is voluntarily recalling Green Giant Fresh whole yellow onions in 2 lb. bags, 3 lb. bags, and 5 lb. bags; whole white onions in 2 lb. bags; and whole red onions in 2 lb. bags delivered directly to three UNFI retail distribution centers (DCs) in Fargo, Nor

Benefits of Post-Op Penile Traction Therapy Hold Up Over Time
https://www.medpagetoday.com/urology/prostatecancer/95226

Oct 23rd, 2021 - SCOTTSDALE, Ariz. -- A penile traction therapy (PTT) device produced lasting improvements in men after prostatectomy, a researcher reported. The current data builds on an August 2021 study of 6-month data from 55 men (average age 58.6) who were randomly assigned to control (n=25) or treatment with PTT (n=30) after prostatectomy. The interventions began 1 month post-surgery, and those in the PTT...

HelloFresh Issues Recall Notice for Products containing Onions due to Possible Health Risk
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428245

HelloFresh has been informed by one of its ingredient suppliers that it is conducting a voluntary recall of its onions due to the potential presence of salmonella bacteria.

EveryPlate Issues Recall Notice for Products containing Onions due to Possible Health Risk
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428244

EveryPlate has been informed by one of its ingredient suppliers that it is conducting a voluntary recall of its onions due to the potential presence of salmonella bacteria.

EveryPlate Issues Recall Notice for Products containing Onions due to Possible Health Risk
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428243

EveryPlate has been informed by one of its ingredient suppliers that it is conducting a voluntary recall of its onions due to the potential presence of salmonella bacteria.

HelloFresh Issues Recall Notice for Products containing Onions due to Possible Health Risk
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428242

HelloFresh has been informed by one of its ingredient suppliers that it is conducting a voluntary recall of its onions due to the potential presence of salmonella bacteria.

Continuous-Release Anti-VEGF Device for AMD Wins FDA Approval
https://www.medpagetoday.com/ophthalmology/generalophthalmology/95225

Oct 23rd, 2021 - The FDA has approved a first-of-its kind continuous delivery system for anti-VEGF therapy for neovascular (wet) age-related macular degeneration (AMD). The Susvimo ocular implant continuously releases 100 mg/mL of ranibizumab directly to the retina over 6 months. Initial implantation and refill can be performed during an office visit with an ophthalmologist. In contrast, conventional intravitre...

Source Implicated in Fatal Case in Georgia: Multistate Outbreak of Non-travel Associated Burkholderia pseudomallei Infections (Melioidosis) in Four Patients: Georgia, Kansas, Minnesota, and Texas-2...
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428236

Testing at the Centers for Disease Control and Prevention (CDC) has identified the bacterial DNA of Burkholderia pseudomallei in an aromatherapy room spray in the home of the Georgia resident who was infected with and died from Burkholderia pseudomallei infection (melioidosis) in July 2021. This Georgia patient was the fourth melioidosis case in a cluster since March 2021 that involved three ot...

Gustavo Fonseca, MD, FACP, Manish Patel, MD, and James Reeves, MD, Co-Author Integrated Safety Analysis of Umbralisib in Lymphoid Malignancies
https://www.onclive.com/view/gustavo-fonseca-md-facp-manish-patel-md-and-james-reeves-md-co-author-integrated-safety-analysis-of-umbralisib-in-lymphoid-malignancies

Oct 22nd, 2021 - Three medical oncologists at Florida Cancer Specialists & Research Institute (FCS) are co-authors on a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies. FCS Director of Clinical Research Gustavo Fonseca, MD, FACP, Director of Drug Development Manish Patel, MD and James Reeves, MD, a member of the FCS clinical research team, participated in the study entitled Int...

Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer
https://www.onclive.com/view/agenus-withdraws-bla-for-balstilimab-in-metastatic-cervical-cancer

Oct 22nd, 2021 - The immuno-oncology company Agenus has made the decision to withdraw its biologic license application (BLA) for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.1 The decision follows the full approval of pembrolizumab (Keytruda) on October 13, 2021, for use as a single agent in pat...

Children With Cancer At Higher Risk for Severe Illness from COVID-19
https://www.onclive.com/view/children-with-cancer-at-higher-risk-for-severe-illness-from-covid-19

Oct 22nd, 2021 - Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher in this patient population compared with the general pediatric population, providing evidence that children with cancer are at higher risk of developing severe illness from C...

Motor imagery improves MS
https://www.mdedge.com/neurology/article/247794/multiple-sclerosis/motor-imagery-improves-ms
Jim Kling

Oct 22nd, 2021 - Motor imagery (MI) is a useful tool in the management of multiple sclerosis (MS), with the potential to improve balance, walking, and even cognitive function and mental health. It’s a technique that many think of as the realm of professional athletes, who use it to help mentally prepare for physical activity.

Oncopeptides Withdraws Melphalan Flufenamide Myeloma Indication in the United States
https://www.onclive.com/view/oncopeptides-withdraws-melphalan-flufenamide-myeloma-indication-in-the-united-states

Oct 22nd, 2021 - Oncopeptides AB (publ) has made the decision to withdraw the indication of melphalan flufenamide (Pepaxto; melflufen) in combination with dexamethasone in select adult patients with relapsed or refractory multiple myeloma from the US market.1 In February 2021, the FDA approved melflufen plus dexamethasone for use in adult patients with relapsed/refractory multiple myeloma who have received at ...

Dr. Yarchoan on Unique Characteristics of Fibrolamellar Carcinoma
https://www.onclive.com/view/dr-yarchoan-on-unique-characteristics-of-fibrolamellar-carcinoma

Oct 22nd, 2021 - Mark Yarchoan, MD, assistant professor of oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses unique characteristics of fibrolamellar carcinoma (FC). FC is a distinct type of liver cancer, Yarchoan says. Unlike hepatocellular carcinoma (HCC), which typically occurs in older patients who have underlying liver disease like cirrhosis, FC tends to occur in youn...

Dr. Burns on the Promise of Combination Regimens in EGFR Exon 20 Insertion+ and KRAS+ NSCLC
https://www.onclive.com/view/dr-burns-on-the-promise-of-combination-regimens-in-egfr-exon-20-insertion-and-kras-nsclc

Oct 22nd, 2021 - Timothy F. Burns, MD, PhD, medical oncologist, UPMC Hillman Cancer Center, associate professor of medicine, associate program director, Research, Hematology/Oncology Fellowship Program, University of Pittsburgh, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer (NSCLC). Although the approvals of targeted...

Dr. Villaruz on Selecting Between Single-Agent and Combination Immunotherapy in NSCLC
https://www.onclive.com/view/dr-villaruz-on-selecting-between-single-agent-and-combination-immunotherapy-in-nsclc

Oct 22nd, 2021 - Liza C. Villaruz, MD, associate professor of medicine, medical oncologist, Division of Hematology/Oncology, UPMC Hillman Cancer Center, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer (NSCLC). Several single-agent and combination immunotherapy regimens, such as nivolumab (Opdivo) plus ipilimumab (Yervoy), are approved for use in patients w...

COVID-19 Science Update released: October 22, 2021 Edition 110
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428231

The COVID-19 Science Update summarizes new and emerging scientific data for public health professionals to meet the challenges of this fast-moving pandemic. Weekly, staff from the CDC COVID-19 Response and the CDC Library systematically review literature in the WHO COVID-19 database, and select publications and preprints for public health priority topics in the CDC Science Agenda for COVID-19 a...